跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,072 条关于
“NX-0479/GS-6791”
全部
1,072
临床试验
530
药物
454
机构
2
资讯
86
2个月前
Nurix Therapeutics Pipeline Review: BTK Degraders and Targeted Protein Degradation Advance in B-Cell Malignancies
去年
FDA Clears IND for Nurix and Gilead's Novel IRAK4 Degrader GS-6791/NX-0479 for Inflammatory Conditions
去年
Nurix Therapeutics' BTK Degrader NX-5948 Shows Promise in B-Cell Malignancies and Autoimmune Diseases
去年
Nurix and Gilead's IRAK4 Degrader GS-6791 Shows Promise for Inflammatory Skin Diseases in Preclinical Studies
11个月前
Nurix Therapeutics Advances Bexobrutideg Toward Pivotal CLL Trials with Strong Phase 1 Data
2年前
FDA Grants Fast Track Designation to Nurix Therapeutics' NX-5948 for Relapsed/Refractory CLL/SLL
去年
Nurix Therapeutics Advances BTK Degrader NX-5948 and Reinitiates NX-2127 Trial
去年
Nurix Therapeutics' NX-5948 Receives FDA Fast Track for Waldenstrom's Macroglobulinemia
去年
NX Taiwan Achieves Historic Medical Device QMS Certification, First Among Japanese Companies
去年
NX-5948, a Novel BTK Degrader, Shows High Response Rates in Pretreated CLL/SLL
第 1 页,共 9 页
上一页
下一页